Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2832 2024-02-28 14:24:14 |
2 format change Meta information modification 2832 2024-02-29 04:11:01 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ivanov, D.O.; Evsyukova, I.I.; Mazzoccoli, G.; Anderson, G.; Polyakova, V.O.; Kvetnoy, I.M.; Carbone, A.; Nasyrov, R.A. Prenatal Melatonin in Regulation of Childhood Obesity. Encyclopedia. Available online: https://encyclopedia.pub/entry/55667 (accessed on 20 April 2024).
Ivanov DO, Evsyukova II, Mazzoccoli G, Anderson G, Polyakova VO, Kvetnoy IM, et al. Prenatal Melatonin in Regulation of Childhood Obesity. Encyclopedia. Available at: https://encyclopedia.pub/entry/55667. Accessed April 20, 2024.
Ivanov, Dmitry O., Inna I. Evsyukova, Gianluigi Mazzoccoli, George Anderson, Victoria O. Polyakova, Igor M. Kvetnoy, Annalucia Carbone, Ruslan A. Nasyrov. "Prenatal Melatonin in Regulation of Childhood Obesity" Encyclopedia, https://encyclopedia.pub/entry/55667 (accessed April 20, 2024).
Ivanov, D.O., Evsyukova, I.I., Mazzoccoli, G., Anderson, G., Polyakova, V.O., Kvetnoy, I.M., Carbone, A., & Nasyrov, R.A. (2024, February 28). Prenatal Melatonin in Regulation of Childhood Obesity. In Encyclopedia. https://encyclopedia.pub/entry/55667
Ivanov, Dmitry O., et al. "Prenatal Melatonin in Regulation of Childhood Obesity." Encyclopedia. Web. 28 February, 2024.
Prenatal Melatonin in Regulation of Childhood Obesity
Edit

There is a growing awareness that pregnancy can set the foundations for an array of diverse medical conditions in the offspring, including obesity. A wide assortment of factors, including genetic, epigenetic, lifestyle, and diet can influence foetal outcomes. A growing number of studies show that many prenatal risk factors for poor foetal metabolic outcomes, including gestational diabetes and night-shift work, are associated with a decrease in pineal gland-derived melatonin and associated alterations in the circadian rhythm. An important aspect of circadian melatonin’s effects is mediated via the circadian gene, BMAL1, including in the regulation of mitochondrial metabolism and the mitochondrial melatoninergic pathway. Alterations in the regulation of mitochondrial metabolic shifts between glycolysis and oxidative phosphorylation in immune and glia cells seem crucial to a host of human medical conditions, including in the development of obesity and the association of obesity with the risk of other medical conditions. The gut microbiome is another important hub in the pathoetiology and pathophysiology of many medical conditions, with negative consequences mediated by a decrease in the short-chain fatty acid, butyrate. The effects of butyrate are partly mediated via an increase in the melatoninergic pathway, indicating interactions of the gut microbiome with melatonin. Some of the effects of melatonin seem mediated via the alpha 7 nicotinic receptor, whilst both melatonin and butyrate may regulate obesity through the opioidergic system. Oxytocin, a recently recognized inhibitor of obesity, may also be acting via the opioidergic system. The early developmental regulation of these processes and factors by melatonin are crucial to the development of obesity and many diverse comorbidities.

melatonin obesity prenatal circadian postnatal development metabolism mitochondria comorbidity gut

1. Introduction

The rise in childhood obesity is widely recognized as major worldwide health issue [1], not only in western cultures but also in developing countries [2][3]. Unfavourable intrauterine conditions contribute to offspring obesity risk, including when associated with maternal conditions, such as obesity, diabetes, metabolic syndrome, or chronic disorder of three or more functional systems (cardiovascular, gastrointestinal, immune, etc.) as well as from pregnancies being complicated by chronic placental deficiency, preeclampsia, or gestational diabetes [4][5][6]. Childhood obesity can be associated with neonates born heavy for height as well as light for height with associated “catch-up” excessive weight gain [7][8][9]. Internal obesity in the first postnatal months increases the risk of the later development of type 2 diabetes, metabolic syndrome, and cardiovascular and nervous system pathologies [10][11][12]. Such data highlights the importance of the prenatal period in modulating obesity predisposition as well as in indicating the important role that pregnancy has as an “environmental sampling” period for adaptive development. Postnatal factors, such as formula-feeding vs breastfeeding, also contribute to obesity risk as associated health consequences, including an array of childhood and adult cancer. A number of general biological processes have been proposed to underpin the prenatal adaptations that heighten offspring obesity risk, including oxidative stress; epigenetic processes; glucocorticoid effects; as well as the actions of neuroactive steroids, somatolactogenes, and related peptides, such as insulin-like growth factor (IGF-1) and oxytocin [13][14][15].

2. Melatonin, Metabolism, and Mother–Placenta–Fetus Interface

Melatonin is classically known for its role in the regulation of the circadian rhythm following its nighttime release by the pineal gland. Melatonin is a powerful antioxidant, an inducer of endogenous antioxidants, and an anti-inflammatory and optimizer of mitochondrial function. Melatonin effects can be via the melatonin receptors, primarily MT1 and MT2 receptors, as well as via nonreceptor effects. Melatonin is generally regarded as amphiphilic, being able to diffuse through the extramembrane spaces as well as through the bilipid cell membrane. Exogenous melatonin tends to gather around intracellular organelles, especially mitochondria, where it can be actively taken up by transporters [16]. Recent data indicates that melatonin is produced by all mitochondria-containing cells, including high levels of production in the gut and placenta. Recent work also shows melatonin to be produced within mitochondria, where it may act to regulate metabolism, sirtuins, endogenous antioxidants, and the mitochondrial antioxidant/oxidant ratio [17]. Melatonin is therefore a powerful regulator of the mother–placenta–fetus interface [18][19][20][21][22].

3. Placenta and Immune Cells

Preeclampsia and many other pathophysiological and physiological processes in the placenta are intimately linked to changes in the activity and phenotypes of immune cells, including natural killer (NK) cells and macrophages, which are the most common decidual leukocytes [23]. Both NK cells and macrophages show phenotypic changes over the course of pregnancy [23][24]. Both of these immune cell types are regulated by melatonin as well as melatonin-induced BMAL1 and alpha 7 nicotinic acetylcholine receptor (α7nAChR), with autocrine melatonin acting to switch macrophages from an M1-like pro-inflammatory phenotype to an M2-like phenotype [25]. As immune cells are powerful controllers of the survival and function of other cells, including placental, such impacts of melatonin on immune cells are important to placental pathophysiology [26]. It is also of note that an obesogenic diet is associated with significant alterations in placenta-associated immune cells [27], being one mechanism whereby maternal obesity impacts on offspring outcomes. Melatonin is a significant regulator of the poor outcomes associated with maternal obesity and an obesogenic diet [28], with effects partly mediated via alterations in the placenta’s regulation by immune cells.

4. Immune Cells and Mitochondria

The phenotype of immune cells are driven by alterations in mitochondrial metabolic function, primarily mediated by glycolysis in a reactive state and oxidative phosphorylation (OXPHOS) in a more quiescent, M2-like state [29]. This shift in phenotype is evident over the circadian rhythm and is the essence of the immune-pineal axis [30], with pineal melatonin shifting immune cells to a quiescent phenotype unless suppressed by the need for an ongoing immune response, as indicated by an increase in pro-inflammatory cytokines [31]. Circadian melatonin therefore has similar effects to those of autocrine melatonin in the regulation of immune cell phenotype [25], allowing both circadian and cellular melatonin to be important determinants of immune cell function. Variations in melatonin production, both circadian and local, thereby underpin alterations in immune cell mitochondrial function that can drive significant changes in the placenta and developing foetus.
Melatonin effects on mitochondrial function, both direct and via BMAL1, are mediated by an increase in the conversion of pyruvate to acetyl-CoA, thereby increasing ATP production by the tricarboxylic acid (TCA) cycle and OXPHOS [32]. This requires the disinhibition of the pyruvate dehydrogenase complex (PDC), with PDC driving the conversion of pyruvate to acetyl-CoA. As acetyl-CoA is also a necessary co-substate for AANAT and the activation of the mitochondrial melatoninergic pathway, circadian melatonin acts to upregulate mitochondrial melatonin and thereby increase levels of sirtuins and endogenous antioxidant enzymes, including superoxide dismutase (SOD)2 [33][34]. As such, local and circadian melatonin can significantly determine the changing immune responses required in placenta-regulating immune cells via impacts on mitochondrial function. The effects of circadian melatonin, via BMAL1 and possibly the α7nAChR, include the upregulation of mitochondrial melatoninergic pathway.
The initiation of the melatoninergic pathway requires the stabilization of AANAT by different 14-3-3 isoforms; 14-3-3 is evident in mitochondria, with its cellular levels being decreased by factors that are associated with suboptimal placental function and poor foetal outcomes, including increased ceramide levels and the microRNAs, miR-7, miR-375, and miR-451 [35]. This would suggest that factors that increase ceramide and these 14-3-3-regulating miRNAs would be associated with poor outcomes, at least in part, via suboptimal mitochondrial melatoninergic pathway activation and the consequences that this has for cellular function, including immune cell function. As melatonin is produced in all body cells, including placental and foetal, alterations in the regulation of the melatoninergic pathway will be relevant to the survival and function of all cells. However, its most relevant impact on human pathophysiology seems predominantly via alterations in the regulation of mitochondrial function, especially in immune cells.

5. Melatonin and Mitochondria

Mitochondria are also important to trophoblast function, with alterations in trophoblast mitochondrial function evident in conditions associated with offspring obesity, including preeclampsia and gestation diabetes [36][37]. The decrease in trophoblast mitochondrial respiration in gestational diabetes seems mediated by an increase in ceramide [37], with ceramide also shown to increase mitochondrial fusion and mitophagy in preeclampsia trophoblasts [38]. As to whether this is mediated by ceramide’s inhibition of 14-3-3 and therefore the mitochondrial melatoninergic pathway requires investigation. In contrast, preeclampsia may be associated with an increase in trophoblast mitochondrial respiration, although with a decrease in respiratory reserve capacity [39]. Preclinical studies indicate that there may differential effects on mitochondrial function in different placental regions [36]. As well as immune cells, trophoblast mitochondrial function regulation by local and circadian melatonin are clearly relevant to placental changes that increase offspring obesity risk.

6. Maternal Gut Microbiome and Pregnancy

There is increasing interest in the role of the gut dysbiosis and associated gut permeability in a wide array of diverse medical conditions [40][41], including in preeclampsia [42]. A decrease in gut microbiome diversity is associated with a significant drop in levels of the gut microbiome-derived short-chain fatty acid, butyrate [42]. Treatment of a preclinical preeclampsia model with butyrate lowered blood pressure, suggesting a role for butyrate in the regulation and treatment of preeclampsia. Clinical and preclinical data show gestational diabetes and intrauterine growth retardation to also have alterations in the gut microbiome, with probiotics shown to have some efficacy in the management of gestational diabetes patient outcomes [43].
Butyrate has a number of effects that are relevant to its efficacy in such a wide array of medical conditions. Butyrate is readily taken up by intestinal epithelial cells, which maintains the gut barrier. Butyrate is also readily transported across intestinal epithelial cells into the general circulation where it can have impacts on central and body-wide systems. Butyrate is a histone deacetylase (HDAC) inhibitor and therefore a powerful epigenetic regulator, including the rapid and marked upregulation of the μ-opioid receptor [44]. Butyrate also dampens immune and glia cell reactivity, with effects that seem mediated by its optimization of mitochondrial function, including the upregulation of pyruvate dehydrogenase complex (PDC) and therefore of oxidative phosphorylation (OXPHOS) and the tricarboxylic acid (TCA) cycle. Butyrate also increases the activation of the melatoninergic pathway, as shown in intestinal epithelial cells [45], with butyrate able to decrease gut permeability, thereby preventing the effects of circulating lipopolysaccharides (LPS) on immune and other body functions. Butyrate may also regulate the melatoninergic pathway via its conversion of ceramide to glucosyl-ceramide, thereby preventing ceramide’s inhibition of 14-3-3 [46]. Data in primates shows butyrate to significantly modulate trophoblast and placenta development [47].
It is widely accepted that alterations in the gut–liver and gut–brain axes are important to paediatric and adult obesity, with decreased butyrate an important aspect of this [48]. The above would suggest that alterations in butyrate availability prenatally may also be relevant to the early developmental etiology of obesity and its associated complications in children and adults.
The role of butyrate-induced mitochondrial melatonin and OXPHOS will be important to determine in the human placenta as well as its influence on the shift in immune cell activity that are crucial to placenta and foetal development. It has recently been proposed that such processes can drive changes in the foetal gut and associated immune cells, especially γδT cells, with consequences for infant post-natal development [26].
It should also be noted that it is not only recognized prenatal medical conditions, such as IUGR and gestational diabetes, that increase offspring obesity. A number of studies show a variety of prenatal stressors to also have such impacts on human offspring [49]. The effects of different stressors is partly mediated by an increase in corticotropin-releasing hormone in the hypothalamus and amygdala, which then acts on mucosal mast cells to increase tumor necrosis factor α (TNFα), which then increases gut permeability and contributes to gut dysbiosis [50]. As such, some of the effects of prenatal medical conditions may be mediated by the stress associated with the symptoms and diagnosis, with consequences driven partly by gut dysbiosis/permeability. Within such a context, the gut and body mitochondria form two important hubs, with their interactions modulated by the levels of melatonin availability [34].
Overall, alterations in the gut microbiome and butyrate production are intimately linked to the prenatal etiology and postnatal pathophysiology of obesity via processes in a number of different body systems and organs but with communal effects that seem mediated by the mitochondrial melatoninergic pathway.

7. Melatonin and the Alpha 7 Nicotinic Receptor

Melatonin effects may also be via its induction of the α7nAChR, which is positively regulated in a circadian manner by the pineal hormone [51]. As well as being present on the plasma membrane, the α7nAChR is expressed on mitochondria, where it acts to suppress apoptotic processes [52]. Some of the effects attributed to melatonin, including in the regulation of gut permeability, are mediated by melatonin increasing vagal nerve ACh that then activates the α7nAChR [53]. The α7nAChR also acts to dampen immune and glia cell pro-inflammatory activity and to shift cells to a phenotype associated with OXPHOS and a more quiescent phenotype. As to whether this is driven by an α7nAChR-mediated disinhibition of PDC and upregulation of the TCA cycle and the mitochondrial melatoninergic pathway requires investigation. This could suggest that the α7nAChR, like BMAL1, mediates pineal melatonin’s induction of mitochondrial melatonin via PDC disinhibition [54].
There is a decrease in placental α7nAChR mRNA and protein in women with preeclampsia [55], indicating that this would be correlated with the decrease in placental melatonin production that is also evident in this condition [56]. Preeclampsia is also associated with a decrease in pineal melatonin, which may be especially evident in preeclamptic women with non-dipping nighttime blood pressure [57]. Melatonin’s positive regulation of the α7nAChR may also directly regulate obesity, since α7nAChR agonism is associated with decreased food intake [58]. Alterations in α7nAChR levels and activation are relevant to other aspects of obesity, including in modulating the effects of central insulin on hepatic gluconeogenesis. Central insulin effects are mediated via the vagal nerve ACh acting on to the α7nAChR of Kupffer cells and hepatic macrophages, which are dysregulated in high fat diet and insulin resistance and drive many hepatic pathophysiological changes in obesity [59]. Macrophage α7nAChR activation can prevent obesogenic impacts on adipocytes [60], whilst the α7nAChR is decreased in the white adipose tissue of obese individuals [61]. Such data indicates a role for the α7nAChR in the regulation of obesity via impacts on different cells and in different tissues, indicating that its regulation by variations in melatonin availability may be important to different aspects of the pathoetiology and pathophysiology of obesity.
The α7nAChR can be negatively regulated by its uniquely human duplicant dupα7 (CHRFAM7A), suggesting that the differential genetic and epigenetic regulation of α7nAChR and dupα7 will determine many of melatonin’s effects. The relevance of the differential regulation of α7nAChR and dupα7 in the placenta, foetus, and placenta-associated immune cells will be important to determine, including how this modulates the levels and effects of melatonin.

8. Melatonin and the Opioidergic System

Alterations in the opioidergic system, especially via reward regulation, are intimately associated with food intake and its dysregulation in obesity [62]. The opioidergic system is also integral to the associations of depression/mood with alterations in food intake [63]. Preclinical and human data shows the μ-, δ-, and κ-opioid receptors regulate metabolic response to diet [64][65][66]. The opioidergic system is also evident in the placenta and is integral to the regulation of immune responses [63]. Activation of the μ-opioid receptor is classically associated with reward, with a decrease in μ-opioid receptor levels proposed to drive food intake in obese individuals [64]. The activation of the κ-opioid receptor, especially in the amygdala, can be associated with dysphoria in humans [67], with κ-opioid receptor inhibition decreasing food intake in obesity [68]. The knockout of dynorphin, the endogenous κ-opioid receptor agonist, reduces fat mass and increases weight loss in mice [69], indicating a role for dysphoria in the regulation of food intake, commonly referred to as “comfort eating”.
Melatonin is a significant regulator of the opioidergic system, including positively regulating the circadian levels of β-endorphin, the endogenous μ-opioid receptor agonist, as well as decreasing κ-opioid receptor levels, reviewed in Reference [63]. It is also of note that gut microbiome-derived butyrate epigenetically upregulates the μ-opioid receptor [44], suggesting that the optimization of butyrate and melatonin will upregulate the μ-/κ-opioid receptor ratio levels and activity, with consequences for food intake in association with mood regulation. As such, the impact of circadian and local melatonin regulation of prenatal processes in the modulation offspring obesity may be intimately linked to changes in the offspring’s opioidergic system. Clearly, the role of melatonin and maternal-derived butyrate in the regulation of the placental and foetal opioidergic systems require further investigation.
Alterations in the activation of the opioidergic system may also be driven by oxytocin. Oxytocin is classically associated with parturition and mother–baby bonding. However, recent data shows oxytocin to significantly suppress obesity, indicating wider roles in the regulation central and systemic processes [70]. It is also of note that oxytocin is a positive allosteric modulator of the μ-opioid receptor [71], thereby linking oxytocin effects to data showing the role of the μ-opioid receptor in obesity as well as in attachment, nociception, and reward. As melatonin can regulate hypothalamic oxytocin production in rodents [72], it requires investigation as to whether variations in circadian and local melatonin production are relevant to the modulation and development of the oxytocin system in the placenta and foetus.

References

  1. WHO. Facts and Figures on Childhood Obesity. Available online: http://www.who.int/end-childhood-obesity/facts/en/ (accessed on 10 January 2020).
  2. Nittari, G.; Scuri, S.; Petrelli, F.; Pirillo, I.; di Luca, N.M.; Grappasonni, I. Fighting obesity in children from European World Health Organization member states. Epidemiological data, medical-social aspects, and prevention programs. Clin. Ter. 2019, 170, e223–e230.
  3. Xu, S.; Xue, Y. Pediatric obesity: Causes, symptoms, prevention and treatment (Review). Exp. Ther. Med. 2016, 11, 15–20.
  4. Tran, B.X.; Dang, K.A.; Le, H.T.; Ha, G.H.; Nguyen, L.H.; Nguyen, T.H.; Tran, T.H.; Latkin, C.A.; Ho, C.S.H.; Ho, R.C.M. Global Evolution of Obesity Research in Children and Youths: Setting Priorities for Interventions and Policies. Obes. Facts 2019, 12, 137–139.
  5. Whitaker, R.C.; Dietz, W.H. Role of the prenatal environment in the development of obesity. J. Pediatr. 1998, 132, 768–776.
  6. Oken, E.; Gillman, M.W. Fetal Origins of Obesity. Obes. Res. 2003, 11, 496–506.
  7. Hales, C.N.; Ozanne, S.E. The dangerous road of catch-up growth. J. Physiol. 2003, 547, 5–10.
  8. Tappy, L. Adiposity in children born small for gestational age. Int. J. Obes. (Lond.) 2010, 34, 1230.
  9. Hediger, M.L.; Overpeck, M.D.; McGlynn, A.; Kuczmarski, R.J.; Maurer, K.R.; Davis, W.W. Growth and fatness at three to six years of age of children born small- or large-for-gestational age. Pediatrics 1999, 104, e33.
  10. Longo, S.; Bollani, L.; Decembrino, L.; Di Comite, A.; Angelini, M.; Stronati, M. Short-term and long-term sequelae in intrauterine growth retardation (IUGR). J. Matern. Fetal Neonatal. Med. 2013, 26, 222–225.
  11. Voerman, E.; Santos, S.; Inskip, H.; Amiano, P.; Barros, H.; Charles, M.A.; Chatzi, L.; Chrousos, G.P.; Corpeleijn, E.; Crozier, S.; et al. Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes. JAMA 2019, 321, 1702–1715.
  12. Hong, Y.H.; Chung, S.C. Small for gestational age and obesity related comorbidities. Ann. Pediatr. Endocrinol. Metab. 2018, 23, 4–8.
  13. McMullen, S.; Langley-Evans, S.C.; Gambling, L.; Lang, C.; Swali, A.; McArdleet, H.J. A common cause for a common phenotype: The gatekeeper hypothesis in fetal programming. Med. Hypotheses. 2012, 78, 88–94.
  14. Cottrell, E.C.; Seckl, J.R. Prenatal stress, glucocorticoids and the programming of adult disease. Front. Behav. Neurosci. 2009, 3, 19.
  15. Thompson, L.P.; Al-Hasan, Y. Impact of Oxidative Stress in Fetal Programming. J. Pregnancy 2012, 2012, 582748.
  16. Reiter, R.J.; Rosales-Corral, S.; Tan, D.X.; Jou, M.J.; Galano, A.; Xu, B. Melatonin as a mitochondria-targeted antioxidant: One of evolution’s best ideas. Cell Mol. Life Sci. 2017, 74, 3863–3881.
  17. Meng, H.; Yan, W.Y.; Lei, Y.H.; Wan, Z.; Hou, Y.Y.; Sun, L.K.; Zhou, J.P. SIRT3 Regulation of Mitochondrial Quality Control in Neurodegenerative Diseases. Front. Aging Neurosci. 2019, 11, 313.
  18. Reiter, R.J.; Tan, D.X.; Korkmaz, A.; Ma, S. Obesity and metabolic syndrome: Association with chronodisruption, sleep deprivation, and melatonin suppression. An. Med. 2012, 44, 564–577.
  19. Richter, H.G.; Hansell, J.A.; Raut, S.M.; Giussani, D.A. Melatonin improves placental efficiency and birth weight and increases the placental expression of antioxidant enzymes in undernourished pregnancy. J. Pineal Res. 2009, 46, 357–364.
  20. Galano, A.; Tan, D.X.; Reiter, R.J. On the free radical scavenging activities of melatonin’s metabolites, AFMK and AMK. J. Pineal Res. 2013, 54, 245–257.
  21. Lanoix, D.; Lacasse, A.A.; Reiter, R.J.; Vaillancourt, C. Melatonin: The watchdog of villous trophoblast homeostasis against hypoxia/reoxygenation-induced oxidative stress and apoptosis. Mol. Cell. Endocrinol. 2013, 381, 35–45.
  22. Rodriguez, C.; Mayo, J.C.; Sainz, R.M.; Antolini, I.; Herrera, F.; Martin, V.; Reite, R.J. Regulation antioxidant enzymes: A significant role for melatonin. J. Pineal Res. 2004, 36, 1–9.
  23. Jena, M.K.; Nayak, N.; Chen, K.; Nayak, N.R. Role of Macrophages in Pregnancy and Related Complications. Arch. Immunol. Ther. Exp. (Warsz) 2019, 67, 295–309.
  24. Bazhenov, D.O.; Khokhlova, E.V.; Viazmina, L.P.; Furaeva, K.N.; Michailova, V.A.; Kostin, N.A.; Selkov, S.A.; Sokolov, D.I. Characteristics of Natural Killer Cell Interaction with Trophoblast Cells During Pregnancy. Curr. Mol. Med. 2019, 20, 202–219.
  25. Muxel, S.M.; Pires-Lapa, M.A.; Monteiro, A.W.; Cecon, E.; Tamura, E.K.; Floeter-Winter, L.M.; Markus, R.P. NF-κB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N-acetyltransferase (AA-NAT) gene. PLoS ONE 2012, 7, e52010.
  26. Anderson, G.; Betancort Medina, S.R. Autism Spectrum Disorders: Role of Pre- and Post-Natal Gamma Delta (γδ) T Cells and Immune Regulation. Curr. Pharm. Des. 2019, 25, 4321–4330.
  27. Baltayeva, J.; Konwar, C.; Castellana, B.; Mara, D.L.; Christians, J.K.; Beristain, A.G. Obesogenic diet exposure alters uterine natural killer cell biology and impairs vasculature remodeling in mice. Biol. Reprod. 2020, 102, 63–75.
  28. Liang, Z.; Liu, H.; Wang, L.; Chen, Y.; Zhou, T.; Heianza, Y.; Li, W.; Leng, J.; Wang, J.; Gao, R.; et al. Maternal MTNR1B genotype, maternal gestational weight gain, and childhood obesity. Am. J. Clin. Nutr. 2020, 111, 360–368.
  29. Viola, A.; Munari, F.; Sánchez-Rodríguez, R.; Scolaro, T.; Castegna, A. The Metabolic Signature of Macrophage Responses. Front. Immunol. 2019, 10, 1462.
  30. Markus, R.P.; Fernandes, P.A.; Kinker, G.S.; da Silveira Cruz-Machado, S.; Marçola, M. Immune-pineal axis—Acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes. Br. J. Pharmacol. 2018, 175, 3239–3250.
  31. Ponte, G.N.; Cardoso, E.C.; Carneiro-Sampaio, M.M.; Markus, R.P. Pineal melatonin and the innate immune response: The TNF-alpha increase after cesarean section suppresses nocturnal melatonin production. J. Pineal Res. 2007, 43, 365–371.
  32. Anderson, G.; Rodriguez, M.; Reiter, R.J. Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells. Int. J. Mol. Sci. 2019, 20, 5500.
  33. Reiter, R.J.; Tan, D.X.; Rosales-Corral, S.; Galano, A.; Jou, M.J.; Acuna-Castroviejo, D. Melatonin Mitigates Mitochondrial Meltdown: Interactions with SIRT3. Int. J. Mol. Sci. 2018, 19, 2439.
  34. Anderson, G. Gut Dysbiosis Dysregulates Central and Systemic Homeostasis via Decreased Melatonin and Suboptimal Mitochondria Functioning: Pathoetiological and Pathophysiological Implications. Melatonin Res. 2019, 2, 70–85.
  35. Seo, M.; Anderson, G. Gut-Amygdala Interactions in Autism Spectrum Disorders: Developmental Roles via regulating Mitochondria, Exosomes, Immunity and microRNAs. Curr. Pharm. Des. 2019, 25, 4344–4356.
  36. Sferruzzi-Perri, A.N.; Higgins, J.S.; Vaughan, O.R.; Murray, A.J.; Fowden, A.L. Placental mitochondria adapt developmentally and in response to hypoxia to support fetal growth. Proc. Natl. Acad. Sci. USA 2019, 116, 1621–1626.
  37. Mejia, J.F.; Hirschi, K.M.; Tsai, K.Y.F.; Long, M.G.; Tullis, B.C.; Bitter, E.E.K.; Bikman, B.T.; Reynolds, P.R.; Arroyo, J.A. Differential placental ceramide levels during gestational diabetes mellitus (GDM). Reprod. Biol. Endocrinol. 2019, 17, 81.
  38. Ausman, J.; Abbade, J.; Ermini, L.; Farrell, A.; Tagliaferro, A.; Post, M.; Caniggia, I. Ceramide-induced BOK promotes mitochondrial fission in preeclampsia. Cell Death Dis. 2018, 9, 298.
  39. Holland, O.J.; Cuffe, J.S.M.; Dekker Nitert, M.; Callaway, L.; Kwan Cheung, K.A.; Radenkovic, F.; Perkins, A.V. Placental mitochondrial adaptations in preeclampsia associated with progression to term delivery. Cell Death Dis. 2018, 9, 1150.
  40. Anderson, G. Endometriosis Pathoetiology and Pathophysiology: Roles of Vitamin A, Estrogen, Immunity, Adipocytes, Gut Microbiome and Melatonergic Pathway on Mitochondria Regulation. Biomol. Concepts 2019, 10, 133–149.
  41. Anderson, G. Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin. Curr. Pharm. Des. 2019, 25, 3550–3562.
  42. Chang, Y.; Chen, Y.; Zhou, Q.; Wang, C.; Chen, L.; Di, W.; Zhang, Y. Short-chain fatty acids accompanying changes in the gut microbiome contribute to the development of hypertension in patients with preeclampsia. Clin. Sci. (Lond.) 2020, 134, 289–302.
  43. Ferrocino, I.; Ponzo, V.; Gambino, R.; Zarovska, A.; Leone, F.; Monzeglio, C.; Goitre, I.; Rosato, R.; Romano, A.; Grassi, G.; et al. Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM). Sci. Rep. 2018, 8, 12216.
  44. Hou, X.; Weng, Y.; Ouyang, B.; Ding, Z.; Song, Z.; Zou, W.; Huang, C.; Guo, Q. HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring μ-opioid receptor in spinal cord. Brain Res. 2017, 1669, 97–105.
  45. Jin, C.J.; Engstler, A.J.; Sellmann, C.; Ziegenhardt, D.; Landmann, M.; Kanuri, G.; Lounis, H.; Schröder, M.; Vetter, W.; Bergheim, I. Sodium butyrate protects mice from the development of the early signs of non-alcoholic fatty liver disease: Role of melatonin and lipid peroxidation. Br. J. Nutr. 2016.
  46. Anderson, G.; Maes, M. Gut Dysbiosis Dysregulates Central and Systemic Homeostasis via Suboptimal Mitochondrial Function: Assessment, Treatment and Classification Implications. Curr. Top. Med. Chem. 2020.
  47. Kumar, P.; Thirkill, T.L.; Ji, J.; Monte, L.H.; Douglas, G.C. Differential Effects of Sodium Butyrate and Lithium Chloride on Rhesus Monkey Trophoblast Differentiation. PLoS ONE 2015, 10, e0135089.
  48. Guercio Nuzio, S.; Di Stasi, M.; Pierri, L.; Troisi, J.; Poeta, M.; Bisogno, A.; Belmonte, F.; Tripodi, M.; Di Salvio, D.; Massa, G.; et al. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr. Obes. 2017, 12, 446–452.
  49. Lamichhane, N.; Olsen, N.J.; Mortensen, E.L.; Obel, C.; Heitmann, B.L.; Händel, M.N. Associations between maternal stress during pregnancy and offspring obesity risk later in life-A systematic literature review. Obes. Rev. 2020, 21, e12951.
  50. Vanuytsel, T.; van Wanrooy, S.; Vanheel, H.; Vanormelingen, C.; Verschueren, S.; Houben, E.; Rasoel, S.S.; Tόth, J.; Holvoet, L.; Farré, R.; et al. Psychological stress and corticotropin-releasing hormone increase intestinal permeability in humans by a mast cell-dependent mechanism. Gut 2014, 63, 1293–1299.
  51. Markus, R.P.; Silva, C.L.; Franco, D.G.; Barbosa, E.M.; Ferreira, Z.S. Is modulation of nicotinic acetylcholine receptors by melatonin relevant for therapy with cholinergic drugs? Pharmacol. Ther. 2010, 126, 251–262.
  52. Gergalova, G.; Lykhmus, O.; Kalashnyk, O.; Koval, L.; Chernyshov, V.; Kryukova, E.; Tsetlin, V.; Komisarenko, S.; Skok, M. Mitochondria express α7 nicotinic acetylcholine receptors to regulate Ca2+ accumulation and cytochrome c release: Study on isolated mitochondria. PLoS ONE 2012, 7, e31361.
  53. Sommansson, A.; Nylander, O.; Sjöblom, M. Melatonin decreases duodenal epithelial paracellular permeability via a nicotinic receptor-dependent pathway in rats in vivo. J. Pineal Res. 2013, 54, 282–291.
  54. Dyar, K.A.; Ciciliot, S.; Wright, L.E.; Biensø, R.S.; Tagliazucchi, G.M.; Patel, V.R.; Forcato, M.; Paz, M.I.P.; Gudiksen, A.; Solagna, F.; et al. Muscle insulin sensitivity and glucose metabolism are controlled by the intrinsic muscle clock. Mol. Metab. 2013, 3, 29–41.
  55. Zheng, L.; Shi, L.; Zhou, Z.; Chen, X.; Wang, L.; Lu, Z.; Tang, R. Placental expression of AChE, α7nAChR and NF-κB in patients with preeclampsia. Ginekol. Pol. 2018, 89, 249–255.
  56. Lanoix, D.; Guérin, P.; Vaillancourt, C. Placental melatonin production and melatonin receptor expression are altered in preeclampsia: New insights into the role of this hormone in pregnancy. J. Pineal Res. 2012, 53, 417–425.
  57. Bouchlariotou, S.; Liakopoulos, V.; Giannopoulou, M.; Arampatzis, S.; Eleftheriadis, T.; Mertens, P.R.; Zintzaras, E.; Messinis, I.E.; Stefanidis, I. Melatonin secretion is impaired in women with preeclampsia and an abnormal circadian blood pressure rhythm. Ren Fail. 2014, 36, 1001–1007.
  58. McFadden, K.L.; Cornier, M.A.; Tregellas, J.R. The role of alpha-7 nicotinic receptors in food intake behaviors. Front. Psychol. 2014, 5, 553.
  59. Kimura, K.; Tanida, M.; Nagata, N.; Inaba, Y.; Watanabe, H.; Nagashimada, M.; Ota, T.; Asahara, S.; Kido, Y.; Matsumoto, M.; et al. Central Insulin Action Activates Kupffer Cells by Suppressing Hepatic Vagal Activation via the Nicotinic Alpha 7 Acetylcholine Receptor. Cell. Rep. 2016, 14, 2362–2374.
  60. Wu, J.; Jiao, Z.Y.; Li, R.Z.; Lu, H.L.; Zhang, H.H.; Cianflone, K. Cholinergic activation suppresses palmitate-induced macrophage activation and improves acylation stimulating protein resistance in co-cultured adipocytes. Exp. Biol. Med. 2017, 242, 961–973.
  61. Cancello, R.; Zulian, A.; Maestrini, S.; Mencarelli, M.; Della Barba, A.; Invitti, C.; Liuzzi, A.; Di Blasio, A.M. The nicotinic acetylcholine receptor alpha7 in subcutaneous mature adipocytes: Downregulation in human obesity and modulation by diet-induced weight loss. Int. J. Obes. 2012, 3612, 1552–1557.
  62. Nogueiras, R.; Romero-Picó, A.; Vazquez, M.J.; Novelle, M.G.; López, M.; Diéguez, C. The opioid system and food intake: Homeostatic and hedonic mechanisms. Obes. Facts 2012, 5, 196–207.
  63. Peciña, M.; Karp, J.F.; Mathew, S.; Todtenkopf, M.S.; Ehrich, E.W.; Zubieta, J.K. Endogenous opioid system dysregulation in depression: Implications for new therapeutic approaches. Mol. Psychiatry 2019, 24, 576–587.
  64. Karlsson, H.K.; Tuominen, L.; Tuulari, J.J.; Hirvonen, J.; Parkkola, R.; Helin, S.; Salminen, P.; Nuutila, P.; Nummenmaa, L. Obesity is associated with decreased μ-opioid but unaltered dopamine D2 receptor availability in the brain. J. Neurosci. 2015, 35, 3959–3965.
  65. Czyzyk, T.A.; Nogueiras, R.; Lockwood, J.F.; McKinzie, J.H.; Coskun, T.; Pintar, J.E.; Hammond, C.; Tschöp, M.H.; Statnick, M.A. Kappa-Opioid receptors control the metabolic response to a high-energy diet in mice. FASEB J. 2010, 24, 1151–1159.
  66. Czyzyk, T.A.; Romero-Picó, A.; Pintar, J.; McKinzie, J.H.; Tschöp, M.H.; Statnick, M.A.; Nogueiras, R. Mice lacking δ-opioid receptors resist the development of diet-induced obesity. FASEB J. 2012, 26, 3483–3492.
  67. Anderson, G. Pathoetiology and pathophysiology of borderline personality: Role of prenatal factors, gut microbiome, mu- and kappa-opioid receptors in amygdala-PFC interactions. Prog. Neuropsychopharmacol. Biol. Psychiatry 2020, 98, 109782.
  68. Karkhanis, A.; Holleran, K.M.; Jones, S.R. Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction. Int. Rev. Neurobiol. 2017, 136, 53–88.
  69. Sainsbury, A.; Lin, S.; McNamara, K.; Slack, K.; Enriquez, R.; Lee, N.J.; Boey, D.; Smythe, G.A.; Schwarzer, C.; Baldock, P.; et al. Dynorphin knockout reduces fat mass and increases weight loss during fasting in mice. Mol. Endocrinol. 2007, 21, 1722–1735.
  70. Lawson, E.A.; Olszewski, P.K.; Weller, A.; Blevins, J.E. The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis. J. Neuroendocrinol. 2019, 28, e12805.
  71. Meguro, Y.; Miyano, K.; Hirayama, S.; Yoshida, Y.; Ishibashi, N.; Ogino, T.; Fujii, Y.; Manabe, S.; Eto, M.; Nonaka, M.; et al. Neuropeptide oxytocin enhances μ opioid receptor signaling as a positive allosteric modulator. J Pharmacol. Sci. 2018, 137, 67–75.
  72. Juszczak, M.; Krzyminska, A.; Bojanowska, E.; Roszczyk, M. The role of the cAMP/PKA signalling pathway in the inhibitory influence of melatonin on oxytocin and vasopressin secretion from the rat hypothalamo-neurohypophysial system. Endokrynol. Pol. 2018, 69, 560–566.
More
Information
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , , , , ,
View Times: 57
Revisions: 2 times (View History)
Update Date: 29 Feb 2024
1000/1000